Akiyama S, Gottesman MM, Hanover JA, Fitzgerald DJ, Willingham MC, Pastan I (1984) Verapamil enhances the toxicity of conjugates of epidermal growth factor with Pseudomonas exotoxin and antitransferrin receptor with Pseudomonas exotoxin. J Cell Physiol 120:271–279. https://doi.org/10.1002/jcp.1041200303

Article  PubMed  Google Scholar 

Andersson Y, Engebraaten O, Fodstad O (2009) Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo. Br J Cancer 101:1307–1315. https://doi.org/10.1038/sj.bjc.6605312

Article  PubMed  PubMed Central  Google Scholar 

Ballabio A, Bonifacino JS (2020) Lysosomes as dynamic regulators of cell and organismal homeostasis. Nat Rev Mol Cell Biol 21:101–118. https://doi.org/10.1038/s41580-019-0185-4

Article  PubMed  Google Scholar 

Cabrera-Pérez MÁ, Pham-The H, Cervera MF, Hernández-Armengol R, Miranda-Pérez de Alejo C, Brito-Ferrer Y (2018) Integrating theoretical and experimental permeability estimations for provisional biopharmaceutical classification: application to the WHO essential medicines. Biopharm Drug Dispos 39:354–368. https://doi.org/10.1002/bdd.2152

Article  PubMed  Google Scholar 

Chang HL, Schwettmann B, McArthur HL, Chan IS (2023). Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response. J Clin Invest 133. https://doi.org/10.1172/JCI172156

Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440–446. https://doi.org/10.1158/0008-5472.CAN-09-1947

Article  PubMed  Google Scholar 

Cretella D, Saccani F, Quaini F, Frati C, Lagrasta C, Bonelli M, Caffarra C, Cavazzoni A, Fumarola C, Galetti M, La Monica S, Ampollini L, Tiseo M, Ardizzoni A, Petronini PG, Alfieri RR (2014) Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. Mol Cancer 13:143. https://doi.org/10.1186/1476-4598-13-143

Article  PubMed  PubMed Central  Google Scholar 

Fanotto V, Ongaro E, Rihawi K, Avallone A, Silvestris N, Fornaro L, Vasile E, Antonuzzo L, Leone F, Rosati G, Giuliani F, Bordonaro R, Scartozzi M, De Maglio G, Negri FV, Fasola G, Aprile G (2016) HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. Oncotarget 7:69060–69074. https://doi.org/10.18632/oncotarget.11264

Article  PubMed  PubMed Central  Google Scholar 

Fu Z, Li S, Han S, Shi C, Zhang Y (2022) Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Sig Transduct Targeted Ther 7:93. https://doi.org/10.1038/s41392-022-00947-7

Article  Google Scholar 

Fuchs H, Weng A, Gilabert-Oriol R (2016) Augmenting the efficacy of immunotoxins and other targeted protein toxins by endosomal escape enhancers. Toxins 8:200. https://doi.org/10.3390/toxins8070200

Article  PubMed  PubMed Central  Google Scholar 

Grimm C, Bartel K, Vollmar AM, Biel M (2018) Endolysosomal cation channels and cancer a link with great potential. Pharmaceuticals 11:4. https://doi.org/10.3390/ph11010004

Article  PubMed  PubMed Central  Google Scholar 

Hudis CA (2007) Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357:39–51. https://doi.org/10.1056/NEJMra043186

Article  PubMed  Google Scholar 

Jaffrézou JP, Sikic BI, Laurent G (1994) Cyclosporin A and cyclosporin SDZ PSC 833 enhance anti-CD5 ricin A-chain immunotoxins in human leukemic T cells. Blood 83:482–489

Article  PubMed  Google Scholar 

Kim JS, Jun SY, Kim YS (2020) Critical issues in the deevelopment of immunotoxins for anticancer therapy. J Pharm Sci 109:104–115. https://doi.org/10.1016/j.xphs.2019.10.037

Article  PubMed  Google Scholar 

Kloudová K, Hromádková H, Partlová S, Brtnický T, Rob L, Bartůňková J, Hensler M, Halaška MJ, Špíšek R, Fialová A (2016) Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines. Oncotarget 7:46120–46126. https://doi.org/10.18632/oncotarget.10028

Article  PubMed  PubMed Central  Google Scholar 

Lavaud P, Andre F (2014) Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Med 12:132. https://doi.org/10.1186/s12916-014-0132-3

Article  PubMed  PubMed Central  Google Scholar 

Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, Shifman S, Tu HY, Myers ML, Xu C, Mattar M, Khodos I, Little M, Qeriqi B, Weitsman G, Wilhem CJ, Lalani AS, Diala I, Freedman RA, Lin NU, Solit DB, Berger MF, Barber PR, Ng T, Offin M, Isbell JM, Jones DR, Yu HA, Thyparambil S, Liao WL, Bhalkikar A, Cecchi F, Hyman DM, Lewis JS, Buonocore DJ, Ho AL, Makker V, Reis-Filho JS, Razavi P, Arcila ME, Kris MG, Poirier JT, Shen R, Tsurutani J, Ulaner GA, de Stanchina E, Rosen N, Rudin CM, Scaltriti M (2020) HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discov 10:674–687. https://doi.org/10.1158/2159-8290.CD-20-0215

Article  PubMed  PubMed Central  Google Scholar 

Nahta R (2012) Molecular mechanisms of trastuzumab-based treatment in HER2-overexpressing breast cancer. ISRN Oncol 2012:428062. https://doi.org/10.5402/2012/428062

Article  PubMed  PubMed Central  Google Scholar 

Pegram MD, Miles D, Tsui CK, Zong Y (2020) HER2-overexpressing/amplified breast cancer as a testing ground for antibody-drug conjugate drug development in solid tumors. Clin Cancer Res 26:775–786. https://doi.org/10.1158/1078-0432.CCR-18-1976

Article  PubMed  Google Scholar 

Pirker R, FitzGerald DJ, Willingham MC, Pastan I (1988) Enhancement of the activity of immunotoxins made with either ricin A chain or Pseudomonas exotoxin in human ovarian and epidermoid carcinoma cell lines. Cancer Res 48:3919–3923

PubMed  Google Scholar 

Smith WS, Johnston DA, Wensley HJ, Holmes SE, Flavell SU, Flavell DJ (2020) The role of cholesterol on triterpenoid saponin-induced endolysosomal escape of a saporin-based immunotoxin. Int J Mol Sci 21:8734. https://doi.org/10.3390/ijms21228734

Article  PubMed  PubMed Central  Google Scholar 

Song ZT, Zhang LW, Fan LQ, Kong JW, Mao JH, Zhao J, Wang FJ (2018) Enhanced anticancer effect of MAP30-S3 by cyclosproin A through endosomal escape. Anticancer Drugs 29:736–747. https://doi.org/10.1097/CAD.0000000000000649

Article  PubMed  Google Scholar 

Valabrega G, Montemurro F, Aglietta M (2007) Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18:977–984. https://doi.org/10.1093/annonc/mdl475

Article  PubMed  Google Scholar 

Vargason AM, Anselmo AC, Mitragotri S (2021) The evolution of commercial drug delivery technologies. Nat Biomed Eng 5:951–967. https://doi.org/10.1038/s41551-021-00698-w

Article  PubMed  Google Scholar 

von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr, Katherine Investigators (2019) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380:617–628. https://doi.org/10.1056/NEJMoa1814017

Article  Google Scholar 

Wensley HJ, Smith WS, Holmes SE, Flavell SU, Flavell DJ (2021) The effect of small molecule pharmacological agents on the triterpenoid saponin induced endolysosomal escape of saporin and a saporin-based immunotoxin in target human lymphoma cells. Biomedicines 9:300. https://doi.org/10.3390/biomedicines9030300

Article  PubMed  PubMed Central  Google Scholar 

Xiong J, Zhang C, Wu S, Gu X, Cai Y, Xu C, Chen Z, Sun J, Wu X, You X, Huang Z, Xie J (2019) Recombinant cucurmosin-based immunotoxin targeting HER-2 with potent in vitro anti-cancer cytotoxicity. Biochem Biophys Res Commun 513:15–21. https://doi.org/10.1016/j.bbrc.2019.03.090

Article  PubMed  Google Scholar 

Zhang C, Cai Y, Dai X, Wu J, Lan Y, Zhang H, Lu M, Liu J, Xie J (2021) Novel EGFR-bispecific recombinant immunotoxin based on cucurmosin shows potent anti-tumor efficiency in vitro. Oncol Rep 45:493–500. https://doi.org/10.3892/or.2020.7878

Article  PubMed  Google Scholar